Reply to Salma Kaochar, Nicholas Mitsiades’ Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer

Umang Swami; Emmanuel S. Antonarakis; Neeraj Agarwal

doi:10.1016/j.eururo.2020.12.009

Reply to Salma Kaochar, Nicholas Mitsiades’ Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer

Umang Swami, Emmanuel S. Antonarakis, Neeraj Agarwal

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e94-e95
Journal	European Urology
Volume	79
Issue number	3
DOIs	https://doi.org/10.1016/j.eururo.2020.12.009
State	Published - Mar 2021

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2020.12.009

Cite this

Swami, U., Antonarakis, E. S., & Agarwal, N. (2021). Reply to Salma Kaochar, Nicholas Mitsiades’ Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. European Urology, 79(3), e94-e95. https://doi.org/10.1016/j.eururo.2020.12.009

Reply to Salma Kaochar, Nicholas Mitsiades’ Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. / Swami, Umang; Antonarakis, Emmanuel S.; Agarwal, Neeraj.
In: European Urology, Vol. 79, No. 3, 03.2021, p. e94-e95.

Research output: Contribution to journal › Letter › peer-review

Swami, U, Antonarakis, ES & Agarwal, N 2021, 'Reply to Salma Kaochar, Nicholas Mitsiades’ Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer', European Urology, vol. 79, no. 3, pp. e94-e95. https://doi.org/10.1016/j.eururo.2020.12.009

Swami U, Antonarakis ES, Agarwal N. Reply to Salma Kaochar, Nicholas Mitsiades’ Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. European Urology. 2021 Mar;79(3):e94-e95. doi: 10.1016/j.eururo.2020.12.009

Swami, Umang ; Antonarakis, Emmanuel S. ; Agarwal, Neeraj. / Reply to Salma Kaochar, Nicholas Mitsiades’ Letter to the Editor re : Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. In: European Urology. 2021 ; Vol. 79, No. 3. pp. e94-e95.

@article{eaae7e5fa3ad4fd6b12a5872cd80d6a4,

title = "Reply to Salma Kaochar, Nicholas Mitsiades{\textquoteright} Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer",

author = "Umang Swami and Antonarakis, {Emmanuel S.} and Neeraj Agarwal",

year = "2021",

month = mar,

doi = "10.1016/j.eururo.2020.12.009",

language = "English (US)",

volume = "79",

pages = "e94--e95",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Reply to Salma Kaochar, Nicholas Mitsiades’ Letter to the Editor re

T2 - Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer

AU - Swami, Umang

AU - Antonarakis, Emmanuel S.

AU - Agarwal, Neeraj

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85099653534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099653534&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2020.12.009

DO - 10.1016/j.eururo.2020.12.009

M3 - Letter

C2 - 33419681

AN - SCOPUS:85099653534

SN - 0302-2838

VL - 79

SP - e94-e95

JO - European Urology

JF - European Urology

IS - 3

ER -

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this